Alignment Healthcare, Inc. (NASDAQ:ALHC) Q3 2024 Earnings Call Transcript

Alignment Healthcare, Inc. (NASDAQ:ALHC) Q3 2024 Earnings Call Transcript October 29, 2024

Alignment Healthcare, Inc. reports earnings inline with expectations. Reported EPS is $-0.14 EPS, expectations were $-0.14.

Operator: Good afternoon and welcome to Alignment Healthcare Third Quarter 2024 Earnings Conference Call and Webcast. All participants will be in a listen-only mode. [Operator Instructions] Please note, that this event is being recorded. Leading today’s call are John Kao, Founder and CEO; and Thomas Freeman, Chief Financial Officer. Before we begin, we would like to remind you that certain statements made during this call will be forward-looking statements as defined by the Private Securities Litigation Reform Act. These forward-looking statements are subject to various risks and uncertainties and reflect our current expectations based on our beliefs, assumptions and information currently available to us. Descriptions of some of the factors that could cause actual results to differ materially from those forward-looking statements are discussed in more detail in our filings with the SEC, including the Risk Factors section for our annual report on Form 10-K for the fiscal year ended December 31, 2023.

Although we believe our expectations are reasonable, we undertake no obligation to revise any statements to reflect changes that occur after this call. In addition, please note that the company will be discussing certain non-GAAP financial measures that they believe are important in evaluating performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliation of historical non-GAAP financial measures can be found in the press release that is posted on the company’s website and in our Form 10-Q for the fiscal quarter ended September 30, 2024. And with that, I would like to turn the call now to John Kao.

John Kao: Hello and thank you for joining us on our third quarter earnings conference call. For the third quarter 2024, our health plan membership of 182,300 members represented approximately 58% growth year-over-year and once again surpassed our year-end membership guidance of 178,000 to 180,000 members. Total revenue of $692 million grew approximately 52% year-over-year and 62% excluding ACO REACH. Adjusted gross profit of $81 million produced a consolidated MBR of 88.4% which led to adjusted EBITDA of positive $6 million in the quarter. This marks the second quarter in a row where both adjusted gross profit and adjusted EBITDA achieved the high-end of our guidance ranges, placing us on solid footing as we enter the final quarter of the year, and prepare for 2025.

Over the past year, CMS has implemented changes that are aligned with its original vision to reward health plans that deliver better care and value to seniors. Many organizations are struggling to adapt to CMS’s higher star standards and tied to reimbursement, creating an opportunity for companies like Alignment who have unique population health management capabilities to take share at an accelerated pace. Alignment’s MA platform, which provides visibility and control across the enterprise was built to succeed in this new MA paradigm. Our fully integrated data, health plan, and clinical ecosystem capabilities have resulted in consistent star performance, lower utilization metrics, better retention and superior growth outcomes. Our ability to seize the opportunity ahead of us is further evidenced by the strength of our third quarter results.

During the quarter, our Care Anywhere clinical model and real-time visibility into utilization enable us to manage care and control costs, while growing membership close to 60% year-over-year. We believe our year-to-date outcomes are unparalleled in today’s MA environment and a preview of what we can achieve over the coming years as we continue to take share from incumbents. Turning to stars, we are pleased to announce that 98% of our health plan members are in plans rated 4-stars or above for 2025. This marks the eighth consecutive year that our California HMO contract, which represents roughly 86% of our MA membership, has earned a 4-star or above rating. Across our other plans, our HMO contract in Nevada and North Carolina retained its 5-star rating for this third straight year.

As CMS raises the bar on stars cut points, we are only one of 7 plans in the country with a 5-star rating. Meanwhile, our California PPO plan obtained a solid 4.5-star rating outcome. Our success at stars stems from an enterprise-wide cultural commitment to ensuring our members get the best quality care and experience possible. This is driven by daily cross-functional reviews of each specific stars measure across our markets. Our visibility and control has enabled us to deliver consistently strong results while many of our competitors have seen stars declines. While we’re proud of our results, we see room for further improvement by more deeply partnering with our network on access to care. Beyond our rating year 2025 stars scores, which impact our 2026 payment, we see multiple years of meaningful stars tailwinds ahead of us.

For rating year 2026 impacting payment year 2027, CMS is increasing emphasis on HEDIS clinical quality metrics that we historically scored 4.5 to 5 stars on in our California HMO contract. Conversely, CMS is reducing CAFs and admin weightings from 4 to 2. We estimate that the reduction in CAFs and admin weightings would have resulted in an increase to our raw star score by approximately 0.23 during the past rating cycle for our California HMO contract. This gives us even more confidence in our ability to maintain at least 4-stars or greater. For rating year 2027 impacting payment year 2028, CMS is replacing the current reward factor with a Health Equity Index, which rewards plans to enroll a greater than average portion of low income and disabled members and demonstrate high clinical quality.

Importantly, our California HMO contract has a high percentage of low income and disabled membership, which places it in a solid position to benefit from the new Health Equity Index bonus. Furthermore, our California HMO contract doesn’t currently receive any benefit from the reward factor, making the Health Equity Index change a pure tailwind to our star rating. In summary, we believe stars policy changes over the next 2 years give us confidence to maintain our current ratings and create upside to our already strong stars scores. With our stars competitive advantage locked in for payment years ’25 and ’26 and significant tailwinds looking ahead to ’27 and ’28, we believe we are well-positioned to thrive in a stars environment that will likely continue to pressure our competitors over the next several years.

Before I turn the call over to Thomas, I’d like to share some early thoughts on 2025. For the 2025 selling season, we continue to take a portfolio approach to our products and markets. Given our focus on profitability, we are directing capital towards markets where we have the greatest competitive advantage and the highest return on investment. We are pleased with the early activity from our sales channels. And based on the first 2 weeks of results, we believe we are solidly on pace with our 2025 growth target of at least 20%. Beyond growth, we’re equally excited for our margin expansion opportunity ahead of us in 2025. First, we expect cohort improvement from our significant growth this year. Second, we believe our relative advantages on stars and the second phase in of the V28 risk model changes are widening our funding advantages versus competitors, allowing us to maintain competitive benefit offerings, even while bidding for margin improvement.

Third, our weighted average benchmark increase of 5% will exceed expected unit cost increases in 2025. And lastly, while the results of this year are proving that our clinical and operating model is already best-in-class, we expect to see continued improvements as we further scale AVA, our clinical operations, and IPA performance management. With each of these factors in mind, along with continued anticipated SG&A operating leverage improvements next year, we are confident that we can achieve 2025 consensus adjusted EBITDA of approximately $40 million. We look forward to sharing more on our growth and profitability outlook in 2025 as we gain more visibility into our AEP results. In conclusion, we believe the Medicare Advantage industry is at an inflection point where future success will require population health management capabilities, consumer-centric technology and a care delivery culture.

Simply put, we built a better MA mousetrap for seniors who are seeking a member-first experience that simplifies the health care system, improves care coordination and provides greater value. When combined with the scalability of our platform and stars tailwinds on the horizon, we see a multiyear pathway ahead of us to grow profitably, increase margins and establish new geographies using internally generated cash flows. Our mission begins with improving the life of one senior at a time, and I would like to thank each one of our employees for being part of this journey. Your commitment to treating each member like you would your own family member has been and will continue to be the cornerstone of our success. Now, I’ll turn the call over to Thomas to further discuss our financial results and outlook.

Thomas?

Thomas Freeman: Thanks, John. For the quarter ending September 2024, our health plan membership of 182,300 increased 58% year-over-year. Our growth achievements this year have continued to surpass expectations and demonstrate how Alignment’s products, member experience and brand reputation are resonating in the market heading into AEP. Our third quarter revenue of $692 million represented 52% growth year-over-year, and 62% growth excluding ACO REACH, marking our highest revenue growth quarter as a publicly traded company. While we are exceptionally pleased with our growth outcomes year-to-date, our ability to onboard and manage our growth this year is what differentiates alignment versus competitors. Adjusted gross profit in the quarter of $81 million was in line with the high-end of our guidance range, representing an MBR of 88.4%.

To put our growth and margin performance into perspective, we have added more seniors in the last 12 months than in the prior 3 years combined. Meanwhile, due to our strong clinical programs and ability to scale, we have consistently met our adjusted gross profit expectations each quarter throughout 2024. During the third quarter, our new member engagement rate continue to track with expectations even as we onboarded more new members than previously anticipated. Strong engagement support our third quarter utilization results performing in line with expectations. Year-to-date, inpatient admissions per 1,000 of 153 continue to run modestly lower year-over-year, establishing a strong jumping off point for 2025. Turning to OpEx, SG&A in the quarter was $91 million.

Our adjusted SG&A was $75 million, an increase of 8% year-over-year. Adjusted SG&A as a percentage of revenue excluding ACO REACH decline from 16.2% to 10.8% year-over-year, improving by approximately 540 basis points. This significant year-over-year decline reflects the scalability of our operating model and the elimination of one-time costs associated with the in-sourcing of our member experience functions that we incurred beginning in the third quarter of last year. For a year-to-date perspective, our adjusted SG&A as a percentage of revenue excluding ACO REACH has now improved by 310 basis points putting us in a solid position to achieve our full year operating leverage goals. Taken together, Adjusted EBITDA of positive $6 million in Q3 achieved a high-end of our outlook range and marks the second quarter in a row where the enterprise has been adjusted EBITDA profitable.

Our strong year-to-date performance underscores our ability to manage costs while growing quickly and further reinforces our confidence in our 2025 outlook. Turning to the balance sheet, we remain solidly positioned and ended the quarter with $381 million in cash and investments with $105 million to parent company. We expect year-end parent cash to be approximately the same or higher than Q3 parent cash due to the timing of intercompany transfers, which have no impact on total cash. Moving to our guidance. For the fourth quarter, we expect health plan membership to be between 184,000 and 186,000 members, revenue to be in the range of $663 million and $678 million, adjusted gross profit to be between $67 million and $82 million, and adjusted EBITDA to be in the range of a loss of $10 million to positive $5 million.

For the full year 2024, we expect revenue to be in the range of $2.67 billion and $2.68 billion, adjusted gross profit to be between $282 million and $297 million, and adjusted EBITDA to be in the range of a loss of $10 million to positive $5 million. Following another strong quarter of sales activity, we are raising our year-end membership expectation by 6,000 members at the midpoint of our guidance range. Year-to-date, we have raised our year-end membership guidance by 22,000 members at the midpoint and now expect ending membership growth of 55% year-over-year. Higher membership expectations also continue to drive improvement in our full year revenue outlook, which now implies revenue growth of 47% year-over-year and 57% excluding ACO REACH.

Moving on to profitability, we are narrowing our adjusted gross profit and adjusted EBITDA guidance ranges. We are raising the low end to reflect strong year-to-date management of medical utilization and continued SG&A operating leverage. We are also reducing the high-end to reflect the timing of certain clinical initiatives and investments to support our growth, which impact gross profit and incremental variable SG&A expenses, such as commissions, associated with our membership outperformance. From an MBR standpoint, we continue to see our increasing mix of new members as a percentage of total membership modestly increase MBR relative to prior expectations. However, this has continued to be offset by outperformance in our adjusted SG&A as a percentage of revenue outlook.

It’s worth noting that we now expect our adjusted SG&A as a percentage of revenue to be 10.9% at the midpoint of our guidance. Finally, in terms of year-over-year seasonality comparisons, I would remind investors to use the second half as a more comparable baseline than the third and fourth quarters individually due to dynamics affecting the quarterly comparisons. The third quarter of 2023 benefited from atypically favorable prior period releases. Meanwhile, the fourth quarter of 2023 was impacted by unfavorable ACO REACH results and the start of higher inpatient unit costs. As a result of these quarter-to-quarter dynamics, the second half MBR comparison year-over-year is more indicative of regular seasonality. In closing, the strength of our third quarter results places us on solid footing towards our full year profitability guidance as we successfully manage our year of outstanding growth.

Although still early in AEP, we are optimistic about the year ahead. As John mentioned earlier, we continue to anticipate at least 20% growth and are confident that we can achieve consensus of $40 million of adjusted EBITDA for 2025. Taken together, our results this year and our outlook for the next few years demonstrate our ability to scale, balance growth and profitability, and improve healthcare for seniors. With that, let’s open the call to questions. Operator?

Q&A Session

Operator: Thank you. Now, we’ll open the first question. One moment, please. It comes from the line of Ryan Daniels with William Blair. Please proceed.

Ryan Daniels: Yes, guys, congrats on the strong performance. Thanks for taking the questions. John, maybe one for you, and it might tie to something Thomas just said on clinical initiatives that you’re investing in. But as we go back roughly a year ago, you talked about investing in some local market relations with providers and brokers. You just mentioned the deeper investments and internalizing member experience. Can you maybe share with us some of the things that you’re doing on a go-forward basis to continue with the spirit of innovation and improvement at the organization?

John Kao: Sure. Sure. Hey, Ryan. Yes, I categorize it as deepening the bench on the ground game and what we’re doing is we are investing in what I would call provider operations. Really kind of end-to-end provider workflows and then automating those workflows in a way that we can really work with our IPAs better and help them surplus faster. We want our provider partners to do better and make more with us. So that’s number one. Number two is, I referred to you as general clinical operations and scaling clinical operations. And so, you’ve heard us talk about Care Anywhere a lot and the efficacy of that program is really, I think, distinguished us. But there’s a lot of other areas that we think there’s opportunities in, including pre-service UM, post-discharge case management, preferred networks where we can improve and work with these — our IPAs and improve access to care and go improve our stars even more.

They’re all in this, I’d categorize as kind of continuous improvement. And that philosophy I think has served us well and is starting to pay off. And all of it I would summarize by saying is getting us, we refer to this a few times in the script, visibility and control of our business. And so we have the data from AVA, we use the data, and we work with internal parts of the company as well as our providers to effect the control. And if we’ve got certain hot spots, we have actively managed those hot spots very effectively. And so this business is so local, you have to have a system that you can use to apply market to market to market to solve problems. And that’s what we’ve done. And I think we’re all benefiting from those results. I hope that helped.

Ryan Daniels: Yes, that’s super helpful color, John. Very insightful. Maybe as my follow-up, either of you can take this, you have really tremendous membership growth throughout the year and it just continues to accelerate. I know, Thomas, you mentioned this is the highest growth rate in sales you’ve experienced as an organization. Is there any one or two things you would attribute to the outperformance versus your expectations, whether it’s kind of internal or just external market dynamics, that’s really helping the company now. Thanks.

John Kao: Yes. Hey, this is John again. I would say the bid process that we’ve undertaken since we really, from the beginning of the company’s inception, but specifically since we’ve been public, we’ve been very disciplined. We haven’t chased growth. We haven’t just hunkered down on margin. We really tried to find the balance between growth and margin. And in 2024, we knew when we were doing the bids, that we were going to have a stars advantage and we were going to have a V28 relative advantage. And we really constructed the bid and the product strategies based on what we thought that unit economic advantage was going to be for us. And it worked. And so if you recall, in ’23, we kind of invested in all of the member experience and member services infrastructure because the best thing we could do is we get the growth, we want to keep all the members and keep them happy.

And so that’s what we did. And so over the last year and a half, all of these investments I think have really paid off. In this business, as you all know, they go in cycles. I think we’re just really well-positioned for the next few years just on a pure unit economic basis on revenue. And I think we’re demonstrating the ability to manage utilization through this model of care that we have and the data transparency that we have. And I think we’ll continue to do that. And we also mentioned that for 2025, we really erred a little bit more on margin expansion. I could see that changing as we head into 2026. And so it’s our approach that has been really the same since day one and it’s working. And it’s because we’re in this for the long-term. This is long-term value creation for all shareholders.

Ryan Daniels: All right, perfect. Thank you so much. Congrats again. Really appreciate it.

Operator: Thank you. Our next question comes from the line of Michael Ha with Baird. Please proceed.

Michael Ha: Hey, thank you. So with your updated ’24 guide narrowing in at slightly lower than previous guide at the midpoint, I think the implied full year MLR is now up about 50, 60 bps. So how much of this is related to new member growth versus these new clinical initiatives versus investments in support growth? Are you seeing any continued uptick in supplemental benefits at all? And then I guess overall, since you’re reaffirming your ’25 consented to adjusted EBITDA, is it fair to say whatever you’re seeing in elevated MLR in fourth quarter basically does not change or shake your confidence at all on 2025?

Thomas Freeman: Yes, absolutely. Hey, Michael, this is Thomas here. So maybe just kind of start big picture and then kind of dive into the full year implied MBR and Q4 update. So I think in terms of where we’re at year-to-date, I think we feel great about where we’re positioned 9 months into 2024. And I think our ability to have raised our membership by 22,000 throughout the year while hitting our quarterly gross profit guidance, something we’re very proud of and really indicates our ability to scale the clinical model and manage utilization throughout the year. In terms of kind of then how we think about the full year update, I think our — the midpoint of our gross profit guidance is a few million lower than previously, but to your exact comment, this really is a function of ongoing investments we’re making to support both the growth outperformance and the back half of 2024 relative to prior expectations as well as starting to ramp up a few incremental investments looking ahead to 2025, where we’re continuing to be pleased with our first 2 weeks of AEP results and continue to expect 20% or greater growth next year as well.

So I think that’s kind of the primary kind of driver for us in terms of the high-end coming down. I think the second thing to your point is, we said last quarter that where we fell in the range for this year would in part depend upon the timing of some of the initiatives that we shared earlier in the year. And I think based on the timing of some of those initiatives, we also pulled down the high-end slightly relative to prior expectations. So, the overall MBR update, I think, from last quarter to this quarter in terms of full year 2024 implied MBR, I think it’s changed by about 40 basis points. And we’ve been able to offset that through continued SG&A leverage given that membership growth outperformance. I think the last thing I would say is, while the new membership has put some incremental pressure on MBR, just given that new members do come in with higher than average MBRs, our utilization has been excellent through the third quarter, and we’re continuing to see strong utilization results through October as well.

So I think, to your question on the 2025 jumping off point, I think our utilization performance to date gives us a lot of confidence in the underlying assumptions in our bid and the achievability of our outlook for next year as well.

Michael Ha: Got it. Thank you. And supplemental benefits, you’re not seeing any further elevated trend there?

Thomas Freeman: No, no. We saw that kind of beginning in the second quarter, and we shared last quarter that it was probably to tune about $5 PMPM running hotter than we previously anticipated. But I would say from the second quarter to the third quarter, no real change in supplemental benefit experience.

Michael Ha: Got it. Thank you. Okay. So my second question, star rating. So it looks like California star rating, overall average at a state level, looks like percent of members in 4-star plus plans are dropping again next year by about, I’m seeing like 3% to 4%. So with alignment being, I think, one of the only MA plans to actually improve. You guys are moving up in tenure [ph] ’26. I was wondering if you could talk about that competitive advantage that that it provides you again once again at the ’26 bids and then also when I think about ’26 and your star ratings improvement the potential growth revenue and earnings benefit, strong move up to 4-stars and 4.5-stars at 5% bonus, 5% [indiscernible] and rebates across I think a high single-digit percent of your members.

I was estimating about 15 million to 25 million of just gross incremental revenue benefit for ’26. And when I compare that to where the street’s at today for ’26, 79 million, it feels like a pretty significant tailwind. I was wondering if you could sort of talk us through how the earnings benefit could look on your outperformance in stars for tenure [ph] ’26. Thank you.

Thomas Freeman: So I think we’re probably not going to get into too much detail on ’26 at this point, just given that we’re kind of focusing on 2025 first and foremost. But I think to your comments on how our stars outperformance versus competitors sets us up for continued growth and market share gains in ’26, the way we typically framed it for investors in the past is that the difference between a 4-star plan and a 3.5-star plan is something to the tune of about 5% of extra revenue per member per month. And the difference between a 4-star plan and a 3-star plan is closer to 10% in terms of extra revenue per member per month. And so depending upon which of our competitors we’re sort of evaluating market-by-market as we contemplate the 2026 bids, I would say on average for many of those competitors, we’ll have somewhere between a 5% to 10% revenue PMPM advantage prior to taking into account how V28 impacts each of us.

And as we shared in the past, V28 is something that we will continue to navigate in terms of our own. Sorry guys, we had an internet issue here. You guys still hear me?

Operator: Yes, we can.

Thomas Freeman: Thank you. So, I think in terms of our V28 setup, we will continue to kind of navigate that as we shared in the past, but what’s really important is similar to stars, we know that many of our competitors are being disproportionately impacted on V28 over the 2024 to 2026 timeframe, given their higher than average starting points under V24. And so, I think that’s another incremental layer of relative advantage we will have, not just in ’24 and ’25, but looking at 2026 as well.

Michael Ha: Thank you.

Operator: Thank you. One moment for our next question, please. It comes from the line of Matthew Gillmor with KeyBanc. Please proceed.

Matthew Dale Gillmor: Hey, good afternoon. I guess I wanted to first make sure I understood the revenue upside in the quarter. And I guess the reason I ask is it looks like you’re maybe implying revenue sequentially a little bit down in the fourth quarter. Was there some sort of revenue pickup in the third quarter, like retroactive members or something like that?

Thomas Freeman: No, I don’t think that was the case. I think as you look out to Q4 you have sort of two things working in tandem. One is the continued membership increase from Q3 to Q4 sequentially. At the same time, we typically expect revenue PMPM to decline over the course of the year given that we have more new members and the new members typically come on with lower revenue PMPM. And also we have just ongoing involuntary disenrollment which tends to be associated with our higher acuity, older higher revenue PMPM members.

Matthew Dale Gillmor: Got it. Makes sense. And then, is there any update to share with respect to Care Anywhere engagement? I think you had a goal of getting to 60% of targeted members by year-end. Just curious where you are on that goal.

Thomas Freeman: Yes, we’re doing a nice job with it. Really, in terms of the new membership in particular was the group we were commenting we wanted to get up from, call it 30% last quarter, up to 60% by year-end. We were able to break the 40% barrier by Q3, which is, again, in line with expectations, and I think particularly noteworthy given that we grew so much more during the third quarter than we originally had contemplated. So I think we’re kind of well on our way in terms of our Care Anywhere heading into Q4 and really have that set for 2025.

Matthew Dale Gillmor: Got it. Thanks, guys.

Thomas Freeman: Thank you.

Operator: Thank you. Our next question comes from the line of Adam Ron with Bank of America. Please proceed.

Adam Ron: Hey, thanks for the questions. I’ve got a couple. So you mentioned that you’re bidding for margin in 2025. And I think last year heading into 2024 you mentioned that you increased the actuarial benefit value by roughly 70 basis points. So, I’m wondering if there’s a similar number you could give for 2025? And also comment, like, in your markets, were other carriers aggressive in cutting benefits, or were they mostly stable?

Thomas Freeman: So, I’m not sure we’re going to share a basis point change in benefit value on today’s call, looking at the 2025, but we have shared with kind of many folks over the past couple months that we did modestly reduce benefits in ’25 relative to ’24, as opposed to your comment on ’24 benefits where we had modestly increased them compared to ’23. So we did pull back on benefits like many others to ensure that we were prioritizing margin improvement for 2025. That being said, I think what John and I have often shared is, we try to take this balanced approach on both growth and profitability. As John commented in 2024, we were probably more like 60-40 growth relative to margin. I think looking ahead to 2025, what we did was we just flipped it the opposite direction, where we were probably more like 60% margin focused, 40% towards growth.

Still balanced in general, but probably prioritizing margin expansion is something greater than growth, given our confidence in our ability to achieve at least 20% next year, given the competitive advantages we have looking ahead.

Adam Ron: That’s helpful. And then if I could hit on a few utilization questions from a different angle. I think last quarter I wrote down that in one half, the inpatient admits per 1,000 was 151, and you expected to decline in two half, but you said that it was 153 year-to-date. So not sure if 3Q came in really hot, or if there was negative interior development or somehow the new members skew it. And then if you could also just hit on Two-Midnight Rule and if you’re seeing anything in Part D the way that, United had described on their recent call. Thanks.

Thomas Freeman: Sure. So let me take each of those there. So in terms of inpatient utilization, Q3 continued to run successful for us in the low to mid 150s, pretty much in line with where we were at relative to expectations. I think the step up between Q2 and Q3 is just sort of normal course kind of variability within a few admits per K, up or down. And as we shared earlier in the year, our Q1 performance, I think, was actually our best ADK [ph] performance to start the year. At the same time, we didn’t expect that that level would necessarily continue throughout 2024. So, I think we’re feeling very good about Q3. And as I mentioned earlier, October inpatient emissions per thousand continue to run in line, if not slightly better than expectations.

In terms of Two-Midnight, we have not experienced an impact on that to date and don’t anticipate experiencing any type of impact on that in the future. As a reminder, in California, we were already operating under a de facto Two-Midnight Rule approach in terms of how we adjudicated claims, and therefore, it was not a significant change for us when that rule officially went into effect. And then lastly, I think your final question was on Part D. I think Part D is interesting and that there’s really no lag from a claim standpoint. We get daily, weekly visibility on our pharmacy utilization from our PBM. And we have not experienced any of the spikes in utilization that some of our peers have commented on in terms of their third-quarter experience.

Adam Ron: That’s all helpful. If I could just squeeze one more in. So, this year, you’re on track to do 200 basis points of margin improvement. And based on your comments, you expect roughly another 100 basis points next year. And you listed out a bunch of tailwinds, but I didn’t hear any headwinds. So just curious if there’s anything we should keep in mind in terms of like keeping down the margin improvement for next year, since you commented that you think next year is a bigger margin improvement year.

Thomas Freeman: Yes, I think we look at it both in terms of MBR and then SG&A as a percentage of revenue. And I think we feel like we’re very well-positioned to drive year-over-year improvement on both MBR and SG&A. And if I were to contrast that with our 2024 experience, you’ve seen where given the significant growth outperformance, it’s put some pressure on our MBR year-over-year, but we’ve actually then been able to more than offset it by improving SG&A as a percentage of revenue. I think looking ahead to 2025, while we anticipate opportunity on both variables for 2025 versus 2024, I would say we probably would expect less SG&A as a percentage of revenue improvement in ’25 relative to what we saw in ’24, just given that we don’t also anticipate growing that 55% next year.

Adam Ron: Perfect. Thank you.

Operator: Thank you. One moment for our next question. That comes from the line of John Ransom with Raymond James. Please proceed.

John Ransom: Hey, good evening, gentlemen. Two questions. If we think about the growth next year, how does that look to you now in terms of existing markets versus new markets. And the second question is, we’re certainly reading a lot of press about the difficulties MA plans are having now contracting downstream with providers. So just any comment on that would be great. Thank you.

John Kao: Hey John, it’s John. We feel good about 2025 growth. We feel good about the mix, we feel good about the margin profile. All the growth is going to be really from existing markets in California with a push toward more market share expansion in the ex-California markets. But overall, what we’ve said is we really are pushing to get to EBITDA and then cash flow positive to fund the new market expansion growth that we anticipate turning back on for ’26 and ’27. And we feel really good about that actually. And what was the second question, John? What was the second one?

John Ransom: Oh gosh, you’re testing my memory, John. That was 30 seconds ago. I’m old. That downstream contracting with providers.

John Kao: Oh, yes.

John Ransom: They’re pushing back on MA, they’re pushing back on all the things they plan to be doing.

John Kao: Yes, but see, to me, it’s a fundamental paradigm shift in what will be successful in Medicare Advantage going forward. And we have said all along that you have to be good at population health management. You have to be able to manage different kinds of cohorts and different kinds of populations. And we’ve always said that, if you know who the sick or chronic and frail or [indiscernible] chronic patients are, you got to take care of them a little differently. And so we take care of them at the home with our own employed clinicians. And so we’ve also said that in an environment where there’s lots of premium to share, it’s okay to kind of do financial engineering and do global CAHP deals. But we’ve also said also that in a single supply chain, having multiple global CAHPS arrangements, it’s really expensive.

And so when there’s margin, or revenue compression with what’s going on with SARS and V28 right now, not — there’s not enough money to go around in pure global CAHPS financial engineering kinds of deals. And so you have to actually have the competency of managing that population internally, which is what we’ve done. And so we’ve done that with the downstream provider partners, both on the physician side as well as the hospital side. And I think that’s what’s allowed us to differentiate ourselves from everybody else. And you heard me say on the previous question, we’re actually trying to expand the surplus of some of the risk pools that we have with IPAs. And all of them are playing with us. Everybody is collaborating and we’re going to make more money for the downstream IPAs, not less.

And that’s a function of, again, having visibility and then having the control in concert with the delivery partners. It’s a different way of thinking about MA than I think the sector has thought about. And I think it’s very much public information now that the way that it was being done isn’t working. And this model that we’re introducing is what we think is the future.

John Ransom: Thank you, sir.

John Kao: Thanks, John.

Operator: Thank you. One moment for our next question, please. And it comes from the line of Whit Mayo with Leerink Partners. Please proceed.

Whit Mayo: Good evening. John, can we just go back to CAHPS again for a minute? I meant the scores just continue to remain kind of challenged, lots of ones and twos this year. Your call center numbers look good, but CAHPS is still challenging. I know there’s stuff with California and the ITAs that’s a disadvantage, but what do you really need to do to do better here? I mean, I heard you with some of the IPA performance management. So like, what’s the fix for this?

John Kao: The fix is foundational in my humble opinion. I think it has to do with the way we contract. It has to do with we delegating certain parts of utilization management to the IPAs. And what we need to do is think of UM not as Nurse Ratched deciding on whether you’re going to get kind of approved or not approved. You have to think of it as care routing and care navigation. And so if somebody wants to get access, what you have to do is you have to say, okay, not only are you approved, but we’re going to actually use our concierge team to help you get access to a specialist or a facility. And so it’s really hard for us to do that when you delegate that away to an IPA because they don’t have the tools or frankly the incentives to do what we need them to do.

And so we need to integrate them into our workflows on UM. That’s the real answer. And so when somebody calls, we’ll be linked into it and we’ll be able to navigate that person to the right care faster. If you want to see your specialist, that you have to see your specialist, it’s 2 months out, that’s one option A. Option B is we have a preferred provider specialist with the same cardiologist that you can see next week. It’s your choice. And I think that care coordination, access to care, are really the kind of exposure points that we’ve had. And we’re kind of redesigning that whole entire workflow. And it’s also linked to the provider operation comment that I made. Now, having said that, we’re still going to have to fix that because I’m not obviously happy with the CAHPS scores.

And it’s not a survey issue or this, that, or the other, which I think the whole thing is kind of crazy that so much of the reimbursement is based on a survey, but be that as it may, the fundamental fix is, I think, access to care and care routing, which the entire company is solving for right now. It’s also going to give us more control into preferred specialists and preferred ancillary providers. And the upside on that extends beyond just improved CAHPS scores, it’s going to extend to just fundamentally better MLRs. That makes sense.

Whit Mayo: Would you describe it as — yes, would you describe it as like a multiyear journey, or do you feel like …

John Kao: No.

Whit Mayo: … okay.

John Kao: No, we started on this year. We’ve said that last year in 2023 was we refer to it as the year of the consumer, ergo all the investments in the sales operations, the member experience. And I think that’s worked really, really well. This year in ’24, it has been the year of the provider, where we’re treating the provider as our partners and our customers, the same way in which we did to the consumers. And it’s been central to our success in terms of managing utilization. And so you’ll — I think you’ll see some of these changes occur with the delivery system as it relates to delegation of certain services. And again, that delegation piece isn’t unique to California. I don’t think you see a lot of delegation of claims or UM outside of California, which for the moment has been an advantage to us relatively, because we’ve kind of been able to make it work.

Others have not. So outside of California, as evidenced by the 5-stars and the efficacy of the care model, I think it’s going to be easier for us, actually, to get kind of, we’re still going to have the stars advantages, we’ll still have the MRA advantages, we’re having good cost management advantages, we really need to focus on the distribution, I think we’ve got good products and we just got to get a little bit bigger. I think that’s the same growth there, even more so.

Whit Mayo: My follow-up, just the IRA Part D stuff, it doesn’t look like you meaningfully changed your Part D deductible at all. I just don’t know what my takeaway is there when seemingly everyone else massively increased it. How are you feeling about this change? How did you land on relative stability in that deductible? Thanks.

Thomas Freeman: Hey, Whit, Thomas here. I think in terms of the Part D deductible comparison, you got to really focus on sort of our more local competitors to our geographies versus the broader national comparison at large. Within our counties, Part D is a very, very important part of the overall benefit offering. Things like $0 PCP copay are just not a competitive differentiator because of the just degree of competitiveness of our counties. So when you kind of think about sort of our position relative to our local competitors, I think we’re kind of very much in line and probably still better than many of them, which gets to the overall benefit richness relative to many of our competitors. But I don’t think it would look kind of like an outlier the way it does if you look at it on a national level.

Whit Mayo: Okay. Thank you.

Operator: Thank you. One moment for our next question. And it comes from the line of Jessica Tassan with Piper Sandler.

Jessica Tassan: Hi, guys. Thanks for taking the question, and congrats on the enrollment. I was wondering if I could follow-up on the capitated contracts. Is there any kind of change in the structure or the nature of the capitated contracts for 2025, either including or excluding supplemental benefits or Part D where they had not previously? And then just is the expectation that MLR in the capitated book is flat, up or down year-over-year in 2025?

Thomas Freeman: Hey, Jess. Thomas here. I would say no change to the construct of our capitated agreements. In California, the IPAs that take global cap typically do not take risk on Part D, nor do they typically take risk on supplement benefits. And largely speaking, we’re not expecting any changes on that for 2025 either. We don’t really comment on the specific nature of all of our different components of MBR, but in terms of kind of the year-over-year global cap group, I wouldn’t expect an MBR change relative to 2024.

Jessica Tassan: Awesome. That’s really helpful. And then I just wanted to follow-up on the Part D question. So, with the redesign impending, can you just help us understand any maybe bid-related or UM actions that Alignment has taken or will take to offset the liability shift in the catastrophic phase of spend? And then, again, just year-over-year, is Part D going to be kind of favorable, neutral, or unfavorable to MLR in ’25 in consideration of those actions? Thanks again.

Thomas Freeman: Yes, yes, happy to cover some of those points. So I think Part D, to your question, is definitely going to become a more important part of overall MLR and gross margin for all MA plans in 2025. And when I think about our approach to that, I think there’s a couple of things that are worth noting. The first would be from an actual financial standpoint, I think it would be a tailwind to overall MLR next year, given that Part D historically, and in terms of how we think about our 2025 bids, we anticipate will continue to be slightly lower than our overall Part C MLR. So I think it will be a tailwind for us heading into next year. I think beyond that, from a more kind of clinical and operational standpoint, we have both a variety of approaches with our PBM to ensure that we’re getting members the right drugs for the right conditions at the right time.

But then from an actual kind of on the ground clinical standpoint, one of the many benefits of the Care Anywhere program is the members that we are engaging with that are high acuity, complex, multiple comorbidities, and are really in need of that more intensive care program, typically they’re ones who are also on many drugs. And I think in many situations our Care Anywhere population is on 10 or 15 drugs, if not more in certain cases. And so I think our ability to leverage our frontline clinicians who are already working with some of these more complex populations, and to continue to make sure that medication adherence and pharmaceutical management is a part of the overall Care Anywhere program will continue to be a competitive advantage for us as the IRA comes into play next year.

Operator: Thank you. One moment for our last question, please. And it comes from the line of Andrew Mok with Barclays. Please proceed.

Unidentified Analyst: Hi. This is Tiffany on for Andrew. You’ve made some meaningful progress on G&A again this quarter. It looks like the implied 2H G&A progression is, like, somewhat different from normal seasonality where there’s an uptick in 2H due to, like, AEP costs. Can you give some color on what might be driving that shift?

Thomas Freeman: Yes, I’m happy to cover that one. So in terms of normal seasonality, the primary driver of the SG&A as a percentage of revenue increasing throughout the year is the timing of our sales and marketing expenses, which are obviously much more concentrated in the back half of the year as compared to the first half of the year, along with ramping up any year zero or new market spend for the following year. And so when you think about 2024 seasonality of SG&A as a percentage of revenue, one of the benefits, or I guess two of the benefits we’re getting are we’re not launching any new states or any major new market expansions for 2025. So we’re saving on year zero expenses. And we are also able to have more economies of scale on our overall sales and marketing spend in the back half of 2024 relative to the back half of 2023.

I’d say the other thing that is more one-time in nature related to the back half of 2023 is we began in-sourcing a number of our member experience functions beginning in the third quarter of last year. And as a result, we had an increase in one-time SG&A in the back half of 2023 that has since lapsed out as we’ve gotten into the back half of 2024. And so part of the improvement year-over-year in 2024 is not having that one-time expense continue this year compared to last year.

Unidentified Analyst: Got it, okay. And then in kind of a similar vein, can you just talk to like sort of the durability of G&A savings we’ve achieved in 2024 as we think about the proper run rate into 2025?

Thomas Freeman: Yes, absolutely. So I think we said a couple of things on that thus far. So, we do anticipate continued SG&A as a percentage of revenue improvement in 2025 relative to 2024. As I said earlier, I don’t think it’s going to be quite to the same extent of year-over-year improvement that we’ve seen in 2024, but I do think we’ll continue to see improvement next year. I think in terms of our kind of medium-term and then longer term goals, what we have said is, first and foremost, we’d like to get SG&A as a percentage of revenue down to 10%. And I’m not sure if we’ll get there next year, but we’re going to continue to make strides towards it. And I think we’ve also said that over the kind of more medium to longer term, we really want to get to 10% SG&A as a percentage of revenue including depreciation, amortization and stock-based comp.

And today we are usually talking about SG&A on an adjusted basis excluding those items just because of the atypical and inflated nature of our stock-based compensation expense due to some accounting implications from when we originally went public and the equity issuances since then. So I think we’re kind of well on our way towards making progress towards that in 2025 and then we’ll continue to probably see improvement towards 10% all in future years.

Jessica Tassan: All right. Got it. Thank you.

Operator: Thank you. One moment for our next question. And it comes from the line of Craig Jones with Stifel. Please proceed.

Craig Jones: I just had a question. Excuse me. I was wondering, if we got this large year one cohort shifting to year two in ’25. How big is that MBR improvement you typically see historically as numbers shift from year one to year two?

Thomas Freeman: Hey, Craig, happy to take that. So in terms of the adverse population where we’re managing the institutional claims, PMPM, historically we’ve seen about 300 basis points of improvement between year one and year two. And I think what’s really important about your point there is not just the cohort improvement opportunity we have looking to 2025, but really the kind of the multiyear embedded profit opportunity as that large bolus of membership in 2024 transitions into year three, year four and beyond in the future years. And as John said earlier, that’s where retention is really the name of the game in this business. And given our kind of performance on retention this year and last year relative to our competitors, I think we feel very good about our ability to continue to keep those members over the next few years as we try to drive those MBRs down into the low 80 range, if not the high 70 range, consistent with our historical cohort performance.

Craig Jones: Okay, great. Thank you.

Operator: Thank you. And with that, as I see no further questions in the queue, I will conclude today’s conference call. Thank you all for participating, and you may now disconnect.